The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT (NCT05914675) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
Track The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation automatically
Every clearance here is in the API, with alerts when new ones post.